sevacizumab
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01847118)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- sevacizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03763123 | Phase 1 | Apr 24, 2018 | Simcere Pharmaceutical Co., Ltd |
| NCT02453464 | Phase 1 | Aug 1, 2015 | Fudan University, Simcere Pharmaceutical Co., Ltd |
| NCT01847118 | Phase 1 | Apr 1, 2013 | Fudan University, Simcere Pharmaceutical Co., Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Simcere Pharmaceutical Co., Ltd | For profit | 3 | 3 | 1 | 2013 |
| Fudan University | Academic/Hospital | 2 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1